The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China; Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No. 123 Huifu West Road, Guangzhou, 510080, China.
Department of Ultrasound, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Acad Radiol. 2022 Dec;29(12):e271-e278. doi: 10.1016/j.acra.2022.03.012. Epub 2022 Apr 30.
This study aimed to develop a model incorporating axillary tail position on mammography (AT) for the prediction of non-sentinel Lymph Node (NSLN) metastasis in patients with initial clinical node positivity (cN+).
The study reviewed a total of 257 patients with cN+ breast cancer who underwent both sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) following neoadjuvant chemotherapy (NAC). A logistic regression model was developed based on these factors and the results of post-NAC AT and axillary ultrasound (AUS).
Four clinical factors with p<0.1 in the univariate analysis, including ycT0(odds ratio [OR]: 4.84, 95% confidence interval [CI]: 2.13-11.91, p<0.001), clinical stage before NAC (OR: 2.68, 95%CI: 1.15-6.58, p=0.025), estrogen receptor (ER) expression (OR: 3.29, 95%CI: 1.39-8.39, p=0.009), and HER2 status (OR: 0.21, 95%CI: 0.08-0.50, p=0.001), were independent predictors of NSLN metastases. The clinical model based on the above four factors resulted in the area under the curve (AUC) of 0.82(95%CI: 0.76-0.88) in the training set and 0.83(95% CI: 0.74-0.92) in the validation set. The results of post-NAC AUS and AT were added to the clinical model to construct a clinical imaging model for the prediction of NSLN metastasis with AUC of 0.87(95%CI: 0.81-0.93) in the training set and 0.89(95%CI: 0.82-0.96) in the validation set.
The study incorporated the results of post-NAC AT and AUS with other clinal factors to develop a model to predict NSLN metastasis in patients with initial cN+ before surgery. This model performed excellently, allowing physicians to select patients for whom unnecessary ALND could be avoided after NAC.
本研究旨在建立一种模型,纳入新辅助化疗(NAC)后乳腺 X 线摄影(AT)中腋窝尾部位置,以预测初始临床淋巴结阳性(cN+)患者的非前哨淋巴结(NSLN)转移。
本研究共纳入 257 例 cN+乳腺癌患者,这些患者在 NAC 后均行前哨淋巴结活检(SLNB)和腋窝淋巴结清扫术(ALND)。基于这些因素和 NAC 后 AT 和腋窝超声(AUS)的结果,建立了一个逻辑回归模型。
单因素分析中,有 4 个临床因素 p<0.1,包括 ycT0(比值比 [OR]:4.84,95%置信区间 [CI]:2.13-11.91,p<0.001)、NAC 前临床分期(OR:2.68,95%CI:1.15-6.58,p=0.025)、雌激素受体(ER)表达(OR:3.29,95%CI:1.39-8.39,p=0.009)和 HER2 状态(OR:0.21,95%CI:0.08-0.50,p=0.001)。这 4 个因素是 NSLN 转移的独立预测因子。基于上述 4 个因素的临床模型,在训练集和验证集中的曲线下面积(AUC)分别为 0.82(95%CI:0.76-0.88)和 0.83(95%CI:0.74-0.92)。将 NAC 后 AUS 和 AT 的结果添加到临床模型中,构建了一个用于预测 NSLN 转移的临床影像学模型,在训练集和验证集中的 AUC 分别为 0.87(95%CI:0.81-0.93)和 0.89(95%CI:0.82-0.96)。
本研究将 NAC 后 AT 和 AUS 的结果与其他临床因素相结合,建立了一种模型,用于预测初始 cN+患者手术前的 NSLN 转移。该模型表现出色,使医生能够选择那些在 NAC 后可以避免不必要的 ALND 的患者。